Key Highlights from EV-302 Study at ESMO 2023

EP: 1.Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers

EP: 2.Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023

EP: 3.Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape

EP: 4.ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer

Now Viewing

EP: 5.Key Highlights from EV-302 Study at ESMO 2023

EP: 6.LITESPARK-003 Trial Insights: Updates from ESMO 2023

EP: 7.Future Opportunities in Genitourinary Cancers

This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.

Daneshmand discusses results from the EV-302 phase 3 trial of enfortumab vedotin (EV) plus pembrolizumab (pembro) vs chemotherapy for first-line treatment of locally advanced or metastatic urothelial carcinoma. He notes that 10% to 20% of patients with bladder cancer present with metastatic disease, with up to 50% progressing post cystectomy. Cisplatin-based chemotherapy has been considered the standard of care for decades.

The EV-302 trial compared EV-pembro with chemotherapy (gemcitabine with cisplatin or carboplatin) in 886 patients. With median 17.2-month follow-up, EV-pembro significantly prolonged progression-free survival (12.5 vs 6.3 months; HR, 0.45) and overall survival (31.5 vs 16.1 months; HR, 0.47), reducing the risk of progression or death by 55% and 53%, respectively. Approximately one-third of patients had a prolonged response to EV-pembro.

Daneshmand believes these results are strong enough to change the standard of care for first-line treatment of advanced urothelial carcinoma to EV-pembro for both cisplatin-eligible and -ineligible patients. He expects rapid adoption of guidelines given the magnitude of benefit demonstrated.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.